Literature DB >> 22660444

Population pharmacokinetics of lamotrigine in Indian epileptic patients.

Surulivelrajan Mallaysamy1, Martin G Johnson, Padma G M Rao, Thiyagu Rajakannan, Lokesh Bathala, Karthik Arumugam, Johan G C van Hasselt, Devarakonda Ramakrishna.   

Abstract

PURPOSE: The aim of this analysis was to describe the pharmacokinetics of oral lamotrigine (LTG) in Indian epileptic patients using a population pharmacokinetic (PPK) modeling approach to confirm that the PK is similar to that of the Caucasian population, and to evaluate and confirm the impact of covariates predictive of inter-individual variability using a simulation platform.
METHODS: Blood samples were obtained from 95 patients, and LTG plasma concentrations were determined. Population PK modeling was performed using NONMEM. A one-compartment PK model with first-order absorption and elimination was used to describe the LTG PK. Log-likelihood profiling and normalized prediction distribution errors (NPDE) were used for model evaluation. A simulation study was performed to investigate dose regimens.
RESULTS: Clearance (CL) was estimated to be 2.27 L/h with inter-individual variability (IIV) of 29 CV%. Volume of distribution (V) was estimated to be 53.6 L (31 CV% IIV). Body weight and concurrent use of carbamazepine and valproate were identified as significant covariates on clearance. Log-likelihood profiling indicated that parameters could be estimated with adequate precision, and NPDE indicated that the model adequately described the data observed. The simulation study illustrated the impact of carbamazepine and valproate on LTG PK, and negligible differences in PK between Indian and Caucasian patients.
CONCLUSIONS: This is the first PK analysis of LTG in Indian patients. The population PK model developed adequately described the data observed. Comparison of identified PK parameters with previous PK analyses in Caucasian patients indicates that CL of LTG is similar, while V is somewhat lower compared with Caucasian patients, but this is not expected to lead to relevant differences in PK profiles during steady state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22660444     DOI: 10.1007/s00228-012-1311-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Effect of antiepileptic drug comedication on lamotrigine clearance.

Authors:  David Weintraub; Richard Buchsbaum; Stanley R Resor; Lawrence J Hirsch
Journal:  Arch Neurol       Date:  2005-09

2.  Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.

Authors:  Z Hussein; J Posner
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

Review 3.  A mechanistic approach to antiepileptic drug interactions.

Authors:  G D Anderson
Journal:  Ann Pharmacother       Date:  1998-05       Impact factor: 3.154

4.  A sensitive and selective HPLC method for estimation of lamotrigine in human plasma and saliva: application to plasma-saliva correlation in epileptic patients.

Authors:  Surulivel Rajan Mallayasamy; Karthik Arumugamn; Tarun Jain; Thiyagu Rajakannan; Krishnamurthy Bhat; Padma Gurumadhavrao; Ramakrishna Devarakonda
Journal:  Arzneimittelforschung       Date:  2010

5.  Prevalence and pattern of epilepsy in India.

Authors:  R Sridharan; B N Murthy
Journal:  Epilepsia       Date:  1999-05       Impact factor: 5.864

6.  Food reduces the bioavailability of lamotrigine.

Authors:  C Sharma; R Dubey; H Kumar; N Saha
Journal:  Indian J Med Res       Date:  2005-05       Impact factor: 2.375

Review 7.  Overview of lamotrigine and the new antiepileptic drugs: the challenge.

Authors:  J M Pellock
Journal:  J Child Neurol       Date:  1997-11       Impact factor: 1.987

8.  Population pharmacokinetics of lamotrigine in patients with epilepsy.

Authors:  J R Milovanovic; S M Jankovic
Journal:  Int J Clin Pharmacol Ther       Date:  2009-12       Impact factor: 1.366

9.  An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels.

Authors:  H Cheung; D Kamp; E Harris
Journal:  Epilepsy Res       Date:  1992-11       Impact factor: 3.045

10.  Antiepileptic drug interactions - principles and clinical implications.

Authors:  Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

View more
  6 in total

1.  Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy.

Authors:  Zhong-Bin Zhang; Shuang-Min Ji; Ying Han; Li-Li Zang; Ying-Hui Wang; Wei Lu; Li Wang; Ye Wu
Journal:  Eur J Clin Pharmacol       Date:  2017-01-07       Impact factor: 2.953

2.  Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

3.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

4.  Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.

Authors:  Shansen Xu; Limin Liu; Yanan Chen; Mei Liu; Tong Lu; Huanxin Wang; Shihao Liu; Mingming Zhao; Limei Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-01-16       Impact factor: 2.953

5.  Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.

Authors:  Branka Brzaković; Katarina Vučićević; Sandra Vezmar Kovačević; Branislava Miljković; Milica Prostran; Žarko Martinović; Milena Pokrajac
Journal:  Eur J Clin Pharmacol       Date:  2013-11-19       Impact factor: 2.953

6.  MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION.

Authors:  Akshanth R Polepally; Page B Pennell; Richard C Brundage; Zachary N Stowe; D Jeffrey Newport; Adele C Viguera; James C Ritchie; Angela K Birnbaum
Journal:  Ann Clin Transl Neurol       Date:  2014-02       Impact factor: 4.511

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.